Benign prostatic hyperplasia

Clinics in Geriatric Medicine

Volumn 26, Issue 2, 2010, Pages 223-239

  Paolone, David R ^a  

^a University of Wisconsin Health   (United States)

Author keywords

Hyperplasia; Lower urinary tract symptoms; Prostate

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; HERBACEOUS AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SILDENAFIL; SILODOSIN; SITOSTEROL; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; TERAZOSIN; TOLTERODINE;

ANAMNESIS; ASTHENIA; BREAST TENDERNESS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FLOPPY IRIS SYNDROME; HOLMIUM LASER; HUMAN; IRIS DISEASE; LABORATORY TEST; LASER PROSTATECTOMY; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MINIMALLY INVASIVE PROCEDURE; MONOTHERAPY; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PATIENT ASSESSMENT; PHYSICAL EXAMINATION; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVIEW; SYMPTOM; THERAPY EFFECT; TRANSURETHRAL ELECTROVAPORIZATION; TRANSURETHRAL INCISION OF THE PROSTATE; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; URINARY TRACT OBSTRUCTION; WATCHFUL WAITING;

AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; LASER THERAPY; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URINATION DISORDERS;

EID: 77953141037     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2010.02.010     Document Type: Review

References (65)

1. Berry S.J., Coffey D.S., Walsh P.C. The development of human benign prostatic hyperplasia with age. J Urol 1984, 132(3):474-479.
2. Harbitz T.B., Haugen O.A. Histology of the prostate in elderly men. A study in an autopsy series. Acta Pathol Microbiol Scand A 1972, 80(60):756-768.
3. Holund B. Latent prostatic cancer in a consecutive autopsy series. San J Urol Nephrol 1980, 14(1):29-35.
4. Franks L.M. Benign nodular hyperplasia of the prostate: a review. Ann R Coll Surg Engl (Lond) 1954, 14:92-106.
5. Reynard J., Lim C.S., Abrams P., et al. The value of multiple free-flow studies in men with lower tract urinary symptoms (LUTS). J Urol 1995, 153:347A.
6. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993, 270(7):860-864.
7. Chicharro-Molero J.A., Burgos-Rodriguez R., Sanchez-Cruz J.J., et al. Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older. J Urol 1998, 159(3):878-882.
8. Bosch J.L., Hop W.C., Niemer A.Q., et al. Parameters of prostate volume and shape in a community based population of men 55 to 74 years old. J Urol 1994, 152(5 Pt 1):1501-1505.
9. Walsh P. Anatomic radical retropubic prostatectomy. Campbell's urology 1998, vol. 3:2565-2588. Elsevier, Philadelphia. P.C. Walsh (Ed.).
10. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003, 44(6):637-649.
11. Kupelian V., McVary K.T., Kaplan S.A., et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston area community health survey. J Urol 2009, 182:616-625.
12. Chute C.G., Panser L.A., Girman C.J., et al. The prevalence of prostatism: a population based survey of urinary symptoms. J Urol 1993, 150:85-89.
13. AUA Practice Guidelines Committee: AUA guideline on management of benign prostatic hyperplasia (2003) Chapter 1: diagnosis and treatment recommendations. J Urol 2003, 170:530-547.
14. Roberts R.O., Jacobsen S.J., Jacobson D.J., et al. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol 2000, 163:107-113.
15. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 1998, 338(9):557-563.
16. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349(25):2387-2398.
17. Hunter D.J., Berra-Unamuno A., Martin-Gordo A. Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years old or older. J Urol 1996, 155(6):1965-1970.
18. Available at:, Accessed December 27, 2009. http://www.uroweb.org.
19. Grossfield G.D., Wolf J.S., Litwin M.S., et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician 2001, 63(6):1145-1154.
20. U.S.Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 149:185-191.
21. Konety B.R., Cooperberg M.R., Carroll P.R., et al. Ann Intern Med 2009, 150(3):220-222. Are age-based criteria the best way to determine eligibility for prostate cancer screening?
22. Kirby R., Lepor H. Evaluation and non-surgical management of benign prostatic hyperplasia. Campbell-Walsh urology 2007, 2766-2802. WB Saunders, Philadelphia. 9th edition. A.J. Wein, L.R. Kavoussi, C.A. Peters (Eds.).
23. Bent S., Kane C., Shinohara K., et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006, 354(6):557-566.
24. Wilt T., Ishani A., Mac Donald R., et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002, (1). CD001044.
25. Berges R.R., Kassen A., Senge T. Treatment of symptomatic benign prostatic hyperplasia with β-sitosterol: an 18-month follow-up. BJU Int 2001, 85:842-846.
26. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 1986, 136:1-4.
27. Price D.T., Schwinn D.A., Lomasney J.W., et al. Identification, quantification, and localization of mRNA for three distinct alpha1 adrenergic receptor subtypes in human prostate. J Urol 1993, 150:546-551.
28. Walden P.D., Gerardi C., Lepor H. Localization and expression of the α1A-1, α1B and α1D adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 1999, 161:635-640.
29. Roehrborn C.G., Schwinn D.A. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004, 171:1029-1035.
30. Smith M.S., Schambra U.B., Wilson K.H., et al. Alpha1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels. Mol Brain Res 1999, 63:254-261.
31. Malloy B.J., Price D.T., Price R.R., et al. Alpha1-adrenergic receptor subtypes in human detrusor. J Urol 1998, 160:937-943.
32. Roehrborn C.G., Oesterling J.E., Auerbach S., et al. Effectiveness and safety of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia in the HYCAT study. Urology 1996, 47:169-178.
33. Lepor H., Kaplan S.A., Klimberg I., et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol 1997, 157:525-530.
34. Lepor H for the Tamsulosin Investigator Group Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998, 51:892-900.
35. Roehrborn C.G. Efficacy and safety of the once daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized placebo-controlled trial. ALFUS study group. Urology 2001, 58:953-959.
36. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. JAMA 2000, 283:1967-1975. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
37. Bell C.M., Hatch W.V., Fisher H.D., et al. Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. JAMA 2009, 301(19):1991-1996.
38. Cantrell M.A., Bream-Rouwenhorst H.R., Steffensmeier A., et al. Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists. Ann Pharmacother 2008, 42(4):558-563.
39. Walsh P.C., Madden J.D., Harrod M.J., et al. Familial incomplete male pseudohermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974, 29:944-949.
40. Imperato-McGinley J., Guerrero L., Gautier T., et al. Steroid 5 alpha reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974, 186:1213-1215.
41. Thigpen A.E., Silver R.I., Guileyardo J.M., et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993, 92(2):903-910.
42. Roehrborn C.G., Boyle P., Nickel J.C., et al. Efficacy and safety of a dual inhibitor of 5 alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002, 60:434-441.
43. Andriole G., Marberger M., Roehrborn C.G. Clinical usefulness of serum prostate specific antigen in the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol 2006, 175:1657-1662.
44. Oesterling J.E., Roy J., Agha A., et al. Biologic variability of prostate specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group. Urology 1997, 50:13-18.
45. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:213-222.
46. Andriole G., Bostwick D., Brawley O., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol 2004, 172:1314-1317.
47. Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996, 335:533-539.
48. Roehrborn C.G., Siami P., Barkin J., et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008, 179:616-621.
49. Lee J.Y., Kim H.W., Lee S.J., et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004, 94:817-820.
50. Kaplan S.A., Roehrborn C.G., Rovner E.S., et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006, 296:2319-2328.
51. McVary K.T., Monnig W., Camps J.L., et al. Sildenafil citrate improves erectile dysfunction and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007, 177:1071-1077.
52. McVary K.T., Roehrborn C.G., Kaminetsky J.C., et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007, 177:1401-1407.
53. Kaplan S.A., Gonzalez R.R., Te A.E. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007, 51:1717-1723.
54. Larson T.R., Bostwick D.G., Corica A. Temperature-correlated histopathologic changes following microwave thermoablation of obstructive tissue in patients with benign prostatic hyperplasia. Urology 1996, 47:463-469.
55. Hoffman R.M., MacDonald R., Monga M., et al. Transurethral microwave thermotherapy vs transurethral resection for treating benign prostatic hyperplasia: a systematic review. BJU Int 2004, 94:1031-1036.
56. US Food and Drug Administration FDA/Medical device safety page Available at:, Accessed January 6, 2010. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm062277.htm.
57. Boyle P., Robertson C., Vaughan E.D., et al. A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int 2004, 94:83-88.
58. Wasson J.H., Reda D.J., Bruskewitz R.C., et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995, 332:75-79.
59. Orandi A. Transurethral incision of the prostate. J Urol 1973, 110:229-231.
60. McConnell J.D., Barry M.D., Bruskewitz R.C., et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical practice guideline 1994, AHCPR, Rockville (MD), Pub No. 94-0582.
61. Turner-Warwick R. An urodynamic review of bladder outlet obstruction in the male and its clinical implications. Urol Clin North Am 1979, 6:171-192.
62. Han M., Partin A. Retropubic and suprapubic open prostatectomy. Campbell-Walsh urology 2007, 2845-2853. WB Saunders, Philadelphia. 9th edition. A.J. Wein, L.R. Kavoussi, C.A. Peters (Eds.).
63. Sotelo R., Spaliviero M., Garcia-Segui A., et al. Laparoscopic retropubic simple prostatectomy. J Urol 2005, 173(3):757-760.
64. Malek R.S., Kuntzman R.S., Barrett D.M. Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol 2005, 174:1344-1348.
65. Elzayat E.A., Elhilali M.M. Holmium laser enucleation of the prostate (HOLEP): long-term results, reoperation rate, and possible impact of the learning curve. Eur Urol 2007, 52:1465-1472.